Lee Pharma inks deal on 2-DG with IICT
City-based LEE Pharma Ltd has entered into a non-exclusive licensing agreement with the CSIR Indian Institute of Chemical Technology, Hyderabad (CSIR-IICT) for process knowhow for synthesis of 2-DG (2-Deoxy-D-Glucose).
image for illustrative purpose
Hyderabad: City-based LEE Pharma Ltd has entered into a non-exclusive licensing agreement with the CSIR Indian Institute of Chemical Technology, Hyderabad (CSIR-IICT) for process knowhow for synthesis of 2-DG (2-Deoxy-D-Glucose).
An anti-Covid drug, named 2- DG (2-deoxy-D-glucose), found to help speed up recovery and reduce oxygen dependence. This drug was already launched in the form of sachets by Dr Reddy's Laboratories. Under the terms of the license agreement, Lee Pharma gets non-exclusive license for the process knowhow for synthesis of 2-DG (2-Deoxy-D-Glucose) covered in the agreement. Lee Pharma will file the application for getting the approval from DCGI, New Delhi. Lee Pharma manufactures and commercialises the 2-DG sachets from their formulation facility located at SEZ, Duvvada, Visakhapatnam. Lee Pharma API manufacturing facility as well as formulation facilities are accreditated by the global regulatory agencies. Raghumitra Alla, Director, Lee Pharma said, "This collaboration with CSIR-IICT for 2-DG (2-Deoxy-D-Glucose) API is part of our broader strategy for enhancing Covid-19 treatment options".
